The FDA's Stance on MDMA Therapy with Dr. Matthew Johnson

Join us as we dive deep into the recent FDA advisory meeting on MDMA therapy for PTSD. In this conversation, we explore the concerns raised by the committee, uncover potential biases, and discuss the impact of prior MDMA use on therapy outcomes. We tackle critical issues such as cardiovascular risk management, the importance of ethical guidelines in psychedelic therapy, and the challenge of functional unblinding. With balanced perspectives, we highlight why MDMA-assisted therapy holds promise despite the controversy. Don’t miss our comprehensive breakdown of the FDA’s stance on MDMA for PTSD and the potential benefits of this groundbreaking treatment.

Receive Exclusive Episodes & Q&A Content by joining our Substack Community: https://www.illusionconsensus.com/

Sponsors
- Alcami Elements :https://www.alcamielements.com/
Receive 10% OFF first order or 30% OFF subscription order using code: ILLUSION

-Brownstone institute: https://brownstone.org/

Timestamps
00:00 Introduction & FDA's recent meeting on MDMA Therapy
28:03 Prior Use of MDMA and its Impact
32:51 The Need for More Expertise in Psychedelics
53:16 The Safety of the Drugs - Valid & Invalid Risks
01:04:35 Comparing the Standards for Evaluating MDMA Therapy
01:19:46 Balancing Risks and Benefits